^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | VT-104 (TEAD inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combination therapy with EGFR tyrosine kinase inhibitors and TEAD inhibitor increases tumor suppression effects in EGFR mutation-positive lung cancer
Published date:
12/06/2023
Excerpt:
The KTOR27 (EGFR kinase domain duplication [KDD]) lung cancer cell lines established from a patient with EGFR mutation-positive lung cancer and commercially available PC-9 and HCC827 (EGFR exon 19 deletions) lung cancer cell lines were used. These cells were used to evaluate the in vitro and in vivo effects of VT104, a TEAD inhibitor....Combination therapy with VT104 and EGFR-TKIs showed better tumor-suppressive effects than EGFR-TKIs alone, in vitro and in vivo.
Secondary therapy:
EGFR inhibitor
DOI:
https://doi.org/10.1158/1535-7163.MCT-23-0371
